This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Cigna files US antitrust claims against Celgene over Pomalyst

( June 24, 2025, 18:35 GMT | Official Statement) -- MLex Summary: Cigna filed a US complaint accusing Celgene of unlawfully extending a monopoly in the market for pomalidomide, a drug used in the treatment of multiple myeloma and sold under the brand name Pomalyst. According to the complaint, Celgene did so through a pattern of fraud at the US Patent Office, by abuse of the federal judicial system and by eventually settling with generic competitors for extended delay of generic entry for years through agreements that protect unlawful supracompetitive pricing.See attached file....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections